Sugi Predict

Sugi Predict / Compounds / SCHEMBL466371

SCHEMBL466371

SCHEMBL466371

[CH2]c1ccc(OCc2ccc(C)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.59
▸ PARP10 Q53GL7 1/20 0.57
▸ NPC1 O15118 3/20 0.56
▸ RAB9A P51151 3/20 0.56
▸ CASP3 P42574 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ SENP8 Q96LD8 1/20 0.56
▸ SENP7 Q9BQF6 1/20 0.56
▸ SENP6 Q9GZR1 1/20 0.56
▸ HRH3 Q9Y5N1 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ APP P05067 4/20 0.50
▸ AGXT P21549 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ MAOA P21397 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8930213 0.89 MAOB (0.69) MAOBPARP10NPC1RAB9ACASP3
SCHEMBL8929713 0.89 MAOB (0.69) MAOBPARP10NPC1RAB9ACASP3
SCHEMBL762195 0.89 MAOB (0.69) MAOBPARP10NPC1RAB9ACASP3
SCHEMBL891195 0.89 MAOB (0.69) MAOBPARP10NPC1RAB9ACASP3
SCHEMBL8599573 0.84 RXRA (0.59) MAOBNPC1RAB9ASMN1; SMN2HRH3
SCHEMBL6014765 0.84 APP (0.67) MAOBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6292403 0.84 APP (0.67) MAOBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL24701846 0.83 MAOB (0.62) MAOBPARP10NPC1RAB9ACASP3
SCHEMBL18635916 0.83 MAOB (0.62) MAOBPARP10NPC1RAB9ACASP3
SCHEMBL11853089 0.83 MAOB (0.62) MAOBPARP10NPC1RAB9ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023179659-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF 江苏恩华药业股份有限公司 2023-09-28 — — WO claimed
US-11931412-B2 JAK1 inhibitors and uses thereof WASHINGTON UNIVERSITY (US) 2024-03-19 — — US disclosed
WO-2023179659-A1 POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF 江苏恩华药业股份有限公司 2023-09-28 — — WO disclosed
US-20210338812-A1 JAK1 INHIBITORS AND USES THEREOF WASHINGTON UNIVERSITY (US) 2021-11-04 — — US disclosed
US-10973913-B2 JAK inhibitors and uses thereof WASHINGTON UNIVERSITY (US) 2021-04-13 — — US disclosed
US-20200282051-A1 JAK INHIBITORS AND USES THEREOF WASHINGTON UNIVERSITY (US) 2020-09-10 — — US disclosed
WO-2017143014-A1 JAK INHIBITORS AND USES THEREOF KIM BRIAN (US) 2017-08-24 — — WO disclosed
US-9650362-B2 Inhibitors PROBIODRUG AG (DE) 2017-05-16 — — US disclosed
US-20160039795-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2016-02-11 — — US disclosed
US-9173885-B2 Inhibitors PROBIODRUG AG (DE) 2015-11-03 — — US disclosed
US-8962860-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-02-24 — — US disclosed
US-8889709-B2 Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions PROBIODRUG AG (DE) 2014-11-18 — — US disclosed
US-20140065095-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2014-03-06 — — US disclosed
US-8486940-B2 Inhibitors PROBIODRUG AG (DE) 2013-07-16 — — US disclosed
EP-2344158-A1 Use of isoQC inhibitors Probiodrug AG (DE) 2011-07-20 — — EP disclosed
US-20110092501-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-04-21 — — US disclosed
US-20100125086-A1 USE OF ISOQC INHIBITORS PROBIODRUG AG (DE) 2010-05-20 — — US disclosed
US-20100119475-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-05-13 — — US disclosed
WO-2010026209-A1 Use of isoQC inhibitors PROBIODRUG AG (DE) 2010-03-11 — — WO disclosed
WO-1998021952-A1 REDUCING AGENT FOR REDUCTIVE ALKYLATION OF GLYCOPEPTIDE ANTIBIOTICS ELI LILLY AND COMPANY (US) 1998-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119475-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, GLUL MAOB 1881/4885PARP10 750/4885NPC1 3997/4885
US-20110092501-A1 NOVEL INHIBITORS GLUL, QPCT, GLS MAOB 928/4885PARP10 1119/4885NPC1 4481/4885
US-20210338812-A1 JAK1 INHIBITORS AND USES THEREOF JAK1, JAK2, JAK3 MAOB 3202/4885PARP10 2182/4885NPC1 1154/4885
US-20160039795-A1 NOVEL INHIBITORS GLUL, QPCT, GLS MAOB 928/4885PARP10 1119/4885NPC1 4481/4885
US-10973913-B2 JAK inhibitors and uses thereof JAK2, JAK1, JAK3 MAOB 1829/4885PARP10 2675/4885NPC1 600/4885
US-11931412-B2 JAK1 inhibitors and uses thereof JAK1, JAK3, JAK2 MAOB 2462/4885PARP10 1829/4885NPC1 1585/4885
US-20140065095-A1 NOVEL INHIBITORS GLUL, QPCT, GLS MAOB 928/4885PARP10 1119/4885NPC1 4481/4885
US-20100125086-A1 USE OF ISOQC INHIBITORS QPCT, QPCTL, GGCT MAOB 3452/4885PARP10 136/4885NPC1 1757/4885
US-20200282051-A1 JAK INHIBITORS AND USES THEREOF JAK2, JAK1, JAK3 MAOB 1829/4885PARP10 2675/4885NPC1 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.